Back Article
    Figure 3个  Table 1个
    • Time interval of collected data Samples Men/women Median Age HPV genotypes Detection method HPV + rate References
      China
      2012–2018 49 29/20 53 16, 18, 52 HPV 16/18 RNA ISH 28.6% Yang et al. (2020)
      2007–2019 152 127/25 NA 11, 16, 18, 33, 53, 58 HPV genotyping 65.1% Xu et al. (2020c)
      2014–2019 257 221/36 60 NA HPV Genotyping 18.3% Xu et al. (2020b)
      1999–2013 300 273/27 54 16, 33, 35, 56, 58, 68 HPV Genotyping and/or p16 IHC 25.0% Chen et al. (2020)
      USA
      2010–2014 1168 926/242 61 NA HPV 16/18 DNA ISH and/or p16 IHC 52.8% White et al. (2020)
      2010–2016 45, 940 38, 0381/7902 60 16, 18, 31, 33, 35, 36, 45, 51, 52, 56, 58, 59, 68, 26, 53, 66, 67, 69, 70, 73, 82, 85 HPV 16/18 DNA ISH and/or p16 IHC 67.5% Rotsides et al. (2020)
      1996–2013 115 101/14 56 NA p16 IHC 90.4% Altenhofen et al. (2020)
      NA 381 332/49 NA NA HPV RNA 79.8% Liu et al. (2020)
      2002–2013 611 517/94 NA NA HPV ISH and p16 IHC 89.0% Elhalawani et al. (2020)
      2007–2018 88 69/19 73 16, 18, 33, 35 PCR amplification of HPV gene loci or p16 IHC 70.5% Dickstein et al. (2020)
      UK
      2010–2016 273 207/66 59 NA p16 IHC 73.3% De Felice et al. (2020)
      Canada
      2005–2017 2039 1668/371 NA NA p16-IHC 48.7% Huang et al. (2020)
      1997–2015 372 0/372a NA NA p16-IHC 56.8% Gazzaz et al. (2019)
      1998–2004 525 381/144 NA NA p16-IHC, HPV DNA ISH 73.5% Hall et al. (2019)
      Australia
      2016–2017 650 284/366 52 16 HPV16 DNA 1.8% Tang et al. (2020)
      2018–2019 910 315/595 37 13, 16, 18, 32 HPV DNA 35.3% Jamieson et al. (2020)
      Australia and New Zealand
      NA 189 NA NA 16, 18 P16 IHC and HPVRNA ISH 88.1% Young et al.(2020a, 2020b)
      Netherlands
      2009–2016 216 143/73 NA NA p16 IHC and HPV DNA 31.9% Chargi et al. (2020)
      1995–2015 168 135/33 NA NA p16 IHC and/or HPV DNA 50.0% Molony et al. (2020)
      Brazil
      1999–2010 346 308/38 55 16 HPV16 and p16 IHC 6.1% Buexm et al. (2020)
      2017–2019 91 78/13 61 NA p16 IHC 20.9% Girardi et al. (2020)
      1984–2014 215 190/25 56 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82 HPV DNA detection and/or p16 IHC 59.1% De Cicco et al. (2020)
      Germany
      2000–2017 102 82/20 57.5 16, 18, 33, 59 HPV genotyping and p16 IHC 40.2% Weiss et al. (2020)
      2000–2011 141 103/38 NA 16 HPV DNA and p16 IHC 34.0% Huebbers et al. (2019)
      2000–2014 323 245/78 58.87 NA HPV DNA and p16 IHC 19.8% Grønhøj et al. (2019a)
      2000–2017 730 NA NA NA HPV DNA and p16 IHC 27.1% Wittekindt et al. (2019)
      2007–2016 92 77/15 NA 16, 18 HPV Genotyping and p16 IHC 71.4% Freitag et al. (2020)
      Denmark
      2000–2017 2169 1564/605 58 16, 18, 33, 25, 59, 26, 31, 45, 56, 11, 58 HPV DNA detection and p16 IHC 55.0% Zamani et al. (2020)
      2000–2014 417 0/417 61.2 NA HPV DNA and p16 IHC 48.7% Christensen et al. (2019)
      2000–2014 993 720/273 59.50 NA HPV DNA and p16 IHC 56.9% Grønhøj et al. (2019a)
      2000–2014 1499 NA NA NA HPV DNA and p16 IHC 55.0% Grønhøj et al. (2019b)
      2000–2014 1243 903/340 60.2 NA HPV DNA and p16 IHC 63.4% Rasmussen et al. (2019)
      Korea
      NA 60 50/10 59 NA HPV DNA detection and p16 IHC 80.0% Suh et al. (2020)
      2004–2013 113 101/12 NA NA HPV Genotyping and p16 IHC 69.9% Kwon et al. (2020)
      Austria
      2014–2019 62 48/14 NA 16, 18, 33, 40, 62, 68 HPV Genotyping or p16 IHC 100% Kofler et al. (2020)
      South Glasgow
      2010–2017 272 NA NA 16. 18. 33. 39. 58 HPV Genotyping 44.0% Zubair et al. (2020)
      Finland
      2000–2016 157 110/47 59.5 NA p16 IHC 9.8% Sievert et al. (2020)
      Spain
      2017–2019 54 43/11 62 NA p16 IHC and HPV DNA 18.5% Viros Porcuna et al. (2020)
      Cameroon
      2014–2015 101 31/70 42 32, 68, 82 p16 IHC and HPV RNA ISH 5.0% Rettig et al. (2019)
      Sweden
      2000–2018 195 123/72 67 NA HPV DNA and p16 IHC 15.9% Hammarstedt et al. (2020)
      Croatia
      2002–2015 99 82/17 60 NA HPV DNA and HPV E6 mRNA 40.4% Božinović et al. (2019)
      Thailand
      2010–2016 110 95/15 59 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, 82 p16 IHC and HPV DNA ISH 14.5% Nopmaneepaisarn et al. (2019)
      Italy
      2010–2017 59 43/16 66 NA HPV DNA 41.2% Ravanelli et al. (2020)
      Studies included in this table meet the following criteria: OPSCC patients; HPV DNA or RNA positive or p16 positive; studies published between January 2019 and October 2020
      aThis study included women with OPSCC only
      IHC: immunohistochemical staining; ISH: in situ hybridization

      Table 1.  Human papillomavirus (HPV) status in relation to oropharyngeal squamous cell carcinoma (OPSCC).